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161 Exhaled nitric oxide; associated with impaired lung function
in CF
E. Yalcin1, N. Gurcan1, G. Cinel1, D. Dogru1, U. Ozcelik1, N. Kiper1. 1Hacettepe
University, Pediatric Pulmonology Department, Ankara, Turkey
Objectives: Fraction of exhaled nitric oxide (FENO) is often reduced in CF. The
aim of this study was to investigate whether FENO level correlates with clinical
parameters, pulmonary function tests, and genotype in CF patients.
Methods: Seventy-two non-smoking CF patients (mean age: 14.6 years (6−34),
35 girls, 37 boys), without evidence of recent or ongoing exacerbation were enrolled
in this study. FENO levels were measured according to the ERS/ATS standard in
72 CF patients. The relation between FENO levels and demographic, genotypic
features, clinical and radiological parameters of the patients was evaluated. The
mean FENO concentration of the 72 patients was 13 ppb (5−45 ppb). Body mass
index (BMI) was <18 in 45% of the patients. Bronchiectasis was detected 77%
of the patients and 44% were chronically infected with P. aeruginosae. Severe
mutation combinations were detected in 48% of the patients, whereas 16% had mild
mutations. FENO level did not correlate with age, BMI, oxygen level, genotypes,
pancreatic status and the presence of P. aeruginosae colonization. There was
a positive correlation between FENO and FEV1 levels (r = 0.3, p = 0.005), and
between FENO levels and “Shwachman-Kulczycki” scores and (r = 0.2, p = 0.033).
The CF patients with bronchiectasis (n = 56) had lower FENO levels (33.6 ppb) than
without bronchiectasis (46.41 ppb) (p = 0.03) group. The FENO concentrations in
patients with FEV1 level 60% (n = 18) had signiﬁcantly lower (27.2 ppb) than in
patients with a FEV1 level >60% (n = 54) (39.5 ppb) (p = 0.03).
Conclusions: Low FENO values might be used as an effective parameter to show
the pulmonary dysfunction and to determine the severity of the disease in CF
patients.
162 Airway inﬂammation in mild cystic ﬁbrosis patients with small
airway disease
M. Rosewich1, O. Eickmeier1, U. Zissler1, F. Serve1, P. Leutz1, R. Schubert1,
S. Zielen1. 1Goethe-University − Children’s Hospital, Allergy, Pneumology and
Cystic Fibrosis, Frankfurt/M, Germany
Background: Airway inﬂammation in patients with cystic ﬁbrosis (CF) plays a
major role in the progression of CF lung disease.
Hypothesis: Sputum cytokine proﬁles in mild CF patients may be different in
patients without and with small airway disease (SAD), deﬁned as MEF25 <50%.
Methods: This was prospectively studied in 27 patients with CF aged 6−55 years
(median 16 years) and 21 controls (median 18 years). The CF patients were divided
into two groups: group 1 (n = 19) without SAD, and group 2 with SAD (n = 9).
Lung function parameters (VC, FEV1, RV, RV/TLC, FEV1%VCmax), cell counts
and cytokines (IL-1, IL-6, IL-8, IL-17, INF-g) were analyzed by quantitative RT-
PCR in induced sputum.
Results: As expected air trapping in patients with SAD signiﬁcantly increased. (RV/
TLC: control: 84.6% − group 1: 109.3% − group 2: 172.1%; p< 0.005). Bronchial
Neutrophils (control: 96% − group 1: 80% − group 2: 45%) and inﬂammatory
markers (i.e. IL-6 and IL-8) in sputum of CF patients were signiﬁcantly different
from controls.
Conclusion: Our study demonstrates that patients with mild disease should be
phenotyped according to their involvement of SAD. Future therapy in mild CF
patients should be aimed to target the small airways more efﬁciently.
163 Expressing change in lung function over time in children with
cystic ﬁbrosis (CF): Which reference equation should we use?
P. Kaiser1,2, R. Suri2,3, J. Kirkby3, J. Stocks3. 1Klinikum Bremen-Mitte, Prof
Hess Children’s Hospital, Bremen, Germany; 2Great Ormond Street Hospital for
Children, London, United Kingdom; 3Portex Unit, UCL Institute of Child Health,
London, United Kingdom
Aim: To assess the appropriateness of 3 commonly applied paediatric reference
equations for detecting change in lung function in children with CF.
Subjects and Methods: 85 children from the CF clinic at Great Ormond Street
Hospital, London,  6 years old with reliable spirometry on 2 occasions 1 year
apart, were included. %predicted values were calculated using reference equations
from Rosenthal (Ros), Knudson (Knu) and Stanojevic (AllAge, AA). Rate of change
was calculated as %pred FEV1 at visit2 − visit1.
Bland and Altman analysis were used to assess the differences between these
equations.
Results: Mean(SD) FEV1 %pred at the 1
st and 2nd visit were 83(19) and 80(19)
%pred using AA, 87(20) and 84(20) %pred [Ros], 85(19) and 82(19) %pred [Knu].
Mean(SD) change in FEV1 %pred over 1 year was −2.8(9.7) using AA,
−3.1(11.1) [Ros] and −3.4(10) [Knu]. AA detected clinically signiﬁcant deterio-
ration with a loss of FEV1 %pred of >10% in 22%; using Ros and Knu more
children had a clinically signiﬁcant deterioration (27% each).
95% limits of agreement for within-subject changes at the ﬁrst visit as well as
inter-subject changes over time were narrower and less skewed when comparing
AA to Knu than to Ros equations.
Conclusion: There are signiﬁcant differences between the 3 equations inﬂuencing
interpretation of respiratory status and therefore clinical management, which require
further investigation. AA provides a stable reference to describe lung function over
time and reliably detects loss of FEV1 at an early age, while the Ros and Knu
equations overestimate FEV1 %pred, especially in young children.
164 Assessment of a commercially available cough counter in healthy
subjects
N. Bauwens1, A.S. Aubriot1, T. Drugman2, T. Dutoit2, T. Leal1, P. Lebecque1.
1Cliniques Universitaires St Luc, Pediatric Pulmonology & Cystic Fibrosis,
Brussels, Belgium; 2Departement of Electrical Engineering, University of Mons,
Mons, Belgium
Background: Reliable cough quantiﬁcation could qualify as a relevant outcome
in CF clinical research but is technically challenging. Preliminary assessment of
a commercially available cough counter (PulmoTrack WHolter™, KarmelSonix,
Haifa, Israel) in CF patients from our centre yielded disappointing results. The
only published validation study of this device has been performed by its developers
in 12 healthy subjects coughing voluntarily. Sensitivity and speciﬁcity >90% under
most circumstances were claimed.
Aim: To verify the accuracy of the PulmoTrack WHolter™ in detecting voluntary
cough sounds while rejecting other sounds with similar characteristics.
Methods: 12 healthy adults contributed to build a database of 1764 sounds.
Following a detailed protocol, each record included for each subject voluntary cough
events from 3 different lung volumes (n = 15), cough epochs with 3 components
(n = 3), forced expirations (n = 3), laughing (n = 3), throat clearing (n = 5) and speech
(n = 5). Recordings were performed in 3 situations: sitting, sitting in a noisy
environment and climbing/going down of a stepladder. Automatic cough counts
by the device were then compared with the recorded sounds, double checked by
two trained observers.
Results: An overall sensitivity of 66 and 70%, with large between-subjects vari-
ations, was observed for cough events and components detection respectively.
Corresponding values for speciﬁcity were 95 and 89%. Most false positive were
related to throat clearing or laughing.
Conclusions: In this study, we were unable to conﬁrm the high sensitivity claimed
for voluntary cough detection in healthy volunteers by the PulmoTrack WHolter™.
